HK1246694A1 - α胸腺肽用於膿毒症治療的用途 - Google Patents

α胸腺肽用於膿毒症治療的用途

Info

Publication number
HK1246694A1
HK1246694A1 HK18106506.4A HK18106506A HK1246694A1 HK 1246694 A1 HK1246694 A1 HK 1246694A1 HK 18106506 A HK18106506 A HK 18106506A HK 1246694 A1 HK1246694 A1 HK 1246694A1
Authority
HK
Hong Kong
Prior art keywords
sepsis
treatment
thymosin alpha
thymosin
alpha
Prior art date
Application number
HK18106506.4A
Other languages
English (en)
Inventor
管向東
吳健鋒
C．塔特希爾
Original Assignee
賽生製藥國際有限公司
中山大學附屬第一醫院
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 賽生製藥國際有限公司, 中山大學附屬第一醫院 filed Critical 賽生製藥國際有限公司
Publication of HK1246694A1 publication Critical patent/HK1246694A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HK18106506.4A 2012-03-30 2018-05-18 α胸腺肽用於膿毒症治療的用途 HK1246694A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261618563P 2012-03-30 2012-03-30
US201261643824P 2012-05-07 2012-05-07
US13/835,107 US20130296223A1 (en) 2012-03-30 2013-03-15 Use of thymosin alpha for the treatment of sepsis

Publications (1)

Publication Number Publication Date
HK1246694A1 true HK1246694A1 (zh) 2018-09-14

Family

ID=49261395

Family Applications (2)

Application Number Title Priority Date Filing Date
HK15108037.1A HK1207314A1 (zh) 2012-03-30 2015-08-19 胸腺素α治療膿毒症的用途
HK18106506.4A HK1246694A1 (zh) 2012-03-30 2018-05-18 α胸腺肽用於膿毒症治療的用途

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK15108037.1A HK1207314A1 (zh) 2012-03-30 2015-08-19 胸腺素α治療膿毒症的用途

Country Status (8)

Country Link
US (5) US20130296223A1 (zh)
EP (2) EP2841088B1 (zh)
JP (5) JP2015514093A (zh)
KR (1) KR20150048663A (zh)
CN (2) CN105338996A (zh)
CA (1) CA2866435A1 (zh)
HK (2) HK1207314A1 (zh)
WO (1) WO2013149030A2 (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015303147A1 (en) * 2014-08-12 2017-02-23 Arsanis Biosciences Gmbh Predicting S. aureus disease
WO2019028448A1 (en) * 2017-08-04 2019-02-07 The Johns Hopkins University APPLICATION FOR EARLY PREDICTION OF SEPTIC SHOCK WAITING
US11504071B2 (en) * 2018-04-10 2022-11-22 Hill-Rom Services, Inc. Patient risk assessment based on data from multiple sources in a healthcare facility
CN111971068A (zh) * 2018-04-20 2020-11-20 康柏辛股份有限公司 败血症和败血性休克的治疗
WO2023285349A1 (en) 2021-07-12 2023-01-19 2N Pharma Aps Carnitine-palmitoyl-transferase-1 (cpt-1) inhibitors for use in a method of preventing or treating sepsis in a mammalian subject

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4079127A (en) 1976-10-28 1978-03-14 Board Of Regents Of The University Of Texas Thymosin alpha 1
AU7964194A (en) * 1993-10-07 1995-05-01 George Washington University Medical Center, The Method of treating septic shock using thymosin-alpha1
TW252045B (zh) * 1993-10-07 1995-07-21 Allan L Goldstein
US5972933A (en) * 1998-01-08 1999-10-26 Ed. Geistlich Sohne Ag Fur Chemische Industrie Method of treating microbial infections
UA80957C2 (en) 2001-11-01 2007-11-26 Sciclone Pharmaceuticals Inc Method of administering a thymosin alpha 1 peptide
NZ540847A (en) * 2002-11-25 2006-07-28 Sciclone Pharmaceuticals Inc Methods of protecting against radiation damage using alpha thymosin
US9205050B2 (en) * 2005-09-29 2015-12-08 Bayer Intellectual Property Gmbh Antibiotic formulations, unit doses, kits and methods
CN101020048A (zh) * 2007-02-12 2007-08-22 广东天普生化医药股份有限公司 一种用于治疗脓毒症的药物组合物
MX2009009657A (es) * 2007-03-21 2009-09-22 Bausch & Lomb Fluoroquinolonas para el tratamiento, reduccion, mejora, o prevencion de las infecciones provocadas por las bacterias resistentes a los farmacos antibacterianos.
EP2240195A4 (en) * 2007-12-12 2011-12-21 Sciclone Pharmaceuticals Inc TREATMENT OF MELANOMA WITH ALPHA-THYMOSIN PEPTIDES IN ASSOCIATION WITH ANTIBODIES AGAINST ANTIGEN 4 ASSOCIATED WITH CYTOTOXIC LYMPHOCYTE T (CTLA4)
CN101514228A (zh) * 2008-02-21 2009-08-26 张卓兵 N-端修饰的人胸腺肽α1复合物及其制备方法
ES2537785T3 (es) * 2009-05-08 2015-06-12 Sciclone Pharmaceuticals, Inc. Péptidos de alfa timosina como potenciadores de vacunas
JP2013520475A (ja) * 2010-02-25 2013-06-06 アゲンニックス・アーゲー 重症敗血症の治療における経口ラクトフェリン
US20140213506A1 (en) * 2011-02-09 2014-07-31 Cynthia W. TUTHILL Thymosin alpha peptide for preventing, reducing the severity of, and treating infection

Also Published As

Publication number Publication date
US20180236036A1 (en) 2018-08-23
EP3741386A1 (en) 2020-11-25
CN107519483A (zh) 2017-12-29
JP2022176345A (ja) 2022-11-25
EP2841088A4 (en) 2015-10-14
JP2015514093A (ja) 2015-05-18
US20240091314A1 (en) 2024-03-21
JP2021100983A (ja) 2021-07-08
KR20150048663A (ko) 2015-05-07
WO2013149030A2 (en) 2013-10-03
CN105338996A (zh) 2016-02-17
EP2841088B1 (en) 2020-06-17
JP2019156854A (ja) 2019-09-19
US20150024994A1 (en) 2015-01-22
HK1207314A1 (zh) 2016-01-29
JP2017214377A (ja) 2017-12-07
CA2866435A1 (en) 2013-10-03
EP2841088A2 (en) 2015-03-04
US20130296223A1 (en) 2013-11-07
US20210106656A1 (en) 2021-04-15

Similar Documents

Publication Publication Date Title
GB2478595B (en) Phytocannabinoids in the treatment of glioma
HK1207583A1 (zh) 生物素治療多發性硬化的用途
GB201321559D0 (en) Diagnosis of the condition of apparatus
HK1246694A1 (zh) α胸腺肽用於膿毒症治療的用途
EP2867239A4 (en) OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF DIABETES
HRP20181879T1 (hr) Spojevi za liječenje pretilosti i postupci za njihovu upotrebu
EP2922536A4 (en) USE OF BUCILLAMINE IN THE TREATMENT OF GOUTTE
GB2508667B (en) Diagnosis of the condition of apparatus
PL2812013T3 (pl) Formulacja do leczenia ibs
AP2015008338A0 (en) Compounds for the treatment and prevention of retroviral infections
HK1202539A1 (zh) -硝呋太爾，其治療感染的用途以及 -硝呋太爾的合成
RS59363B1 (sr) Upotreba inhibitora telomeraze imetelstata za lečenje mijelofibroze
LT2872176T (lt) Karboranilporfirinai, skirti naudoti vėžio gydymui
GB2515440B (en) Vesicular Formulations for use in the treatment of Rosacea
HK1210421A1 (zh) 孕甾- -烯- -炔- -酮用於治療抑鬱症的用途
LT2863932T (lt) Kompozicija, skirta naudoti limfedemos gydymui
GB201208770D0 (en) Compounds for use in the treatment of adenovirus infections